What are the latest sterile infusion options?

September 11, 2025

Understanding the Current Landscape of Sterile Infusion Options

In recent years, sterile infusion methods have undergone significant transformations, driven by technological advancements and responding to critical supply demands. As the demand for sterile infusions rises, especially in home healthcare settings and amid global disruptions, understanding the latest options and their benefits is essential for both healthcare providers and patients. This article delves into the current challenges, innovative solutions, and emerging trends in the sterile infusion industry.

Current Sterile IV Solutions and Their Applications

What are the most common types of IV solutions?

The most common types of intravenous (IV) solutions are essential for a variety of clinical applications. Each type serves specific hydration needs that are crucial for patient care, particularly for those unable to take fluids orally. Here are some frequently used solutions:

IV Solution Composition Clinical Use
0.9% Normal Saline 0.9 grams of NaCl per 100 mL Often used for hypovolemia correction, and preferred maintenance fluid for pediatric patients.
D5 0.45% Normal Saline Dextrose combined with saline Ensures proper osmolality to prevent hemolysis; used when moderate hydration is needed.
D5 0.33% Normal Saline Dextrose with a lower saline conc. Used for patients requiring gradual fluid replacement and calorie supplementation.
D5 0.2% Normal Saline Dextrose at even lower saline conc. Helps maintain hydration in specific patient populations while managing electrolyte balance.
Lactated Ringer's Solution Electrolytes, including lactate Supports patients recovering from metabolic acidosis; popular in surgical settings.

Clinical uses and benefits

Normal saline (0.9% NaCl) is frequently the choice for rapid volume expansion in emergencies and is crucial in avoiding hyponatremia in pediatric care. D5 solutions are beneficial as they combine hydration with caloric intake. For instance, Lactated Ringer's supports metabolic recovery and replenishes electrolytes, making it suitable for more complex conditions.

Overall, the applications of these IV solutions underscore their importance in maintaining fluid and electrolyte balance, aiding in recovery, and ensuring optimal patient outcomes during hospitalization or home infusion therapy.

Variety in Infusion Therapies: Beyond the Basics

What are the main types of infusion therapies?

Infusion therapies primarily include intravenous (IV), intramuscular (IM), and subcutaneous (SQ) methods.

  1. Intravenous (IV) Therapy
    This method delivers fluids, medications, or nutrition directly into the bloodstream. It's commonly used for conditions like severe dehydration and cancer treatment.

    • Advantages : Enables rapid therapeutic effects and precise medication delivery.
    • Side Effects : Potential for redness, swelling, and allergic reactions at the infusion site.
  2. Intramuscular (IM) Infusions
    Medications are injected directly into muscle tissue for rapid absorption. Commonly used for antibiotics and vaccines.

    • Advantages : Quick absorption rate.
    • Side Effects : May cause pain or swelling at the injection site.
  3. Subcutaneous (SQ) Infusions
    This technique allows for slower medication absorption beneath the skin, often used for medications like insulin or blood thinners.

    • Advantages : Allows patients to self-administer medication at home.
    • Side Effects : Possible redness or nausea.

Additionally, IVIG therapy helps restore antibodies in immune-compromised patients and can be delivered via IV or SQ, often requiring pre-medications to minimize side effects.

Choosing the right infusion method ensures optimal treatment outcomes tailored to individual patient needs, highlighting the flexibility and effectiveness of infusion therapies.

Home Infusion Therapy: Growth and Benefits

Overview of home infusion therapy

Home infusion therapy (HIT) is a medical practice where patients receive medications or fluids intravenously or subcutaneously in the comfort of their homes. This therapy encompasses a wide range of treatments including antibiotics, chemotherapy, total parenteral nutrition, and pain management. With advances in technology and medical practices, the home infusion market is expanding rapidly, serving over 3.2 million patients annually in the U.S.

A licensed healthcare provider typically oversees home infusion, ensuring that treatments are administered safely. Various infusion methods are available, such as IV push, elastomeric devices, and infusion pumps, offering tailored solutions based on patient needs and medication types.

Benefits and growth trends

The home infusion market is projected to grow at an impressive rate of 7.5% annually through 2028. This growth reflects an increasing acceptance of home-based therapies, providing several key benefits:

  • Cost-Effective Care : HIT can reduce hospitalization costs, making it a financially appealing option.
  • Comfort and Convenience : Patients benefit from receiving treatment at home, which is often more comfortable.
  • Improved Safety : Home environments can reduce the risk of hospital-acquired infections, especially for immunocompromised patients.

Home infusion therapy is not just a trend; it signifies a transformative approach to patient care, emphasizing personalized, effective treatments while enhancing patients' quality of life.

Addressing the Shortage: Current Challenges in Sterile IV Fluid Supply

Is there a shortage of sterile IV fluids in 2024?

Yes, in 2024, a significant shortage of sterile IV fluids is ongoing. The disruption began when Baxter International's facility in North Carolina, which provides around 60% of the nation's IV fluids, faced closure due to Hurricane Helene. The repercussions of this event have been profound, as evidenced by a recent survey from early October 2024, which found that over 86% of healthcare providers reported shortages. Alarmingly, many facilities were receiving less than half of their usual orders of IV fluids.

As a result, the average stock of IV fluids has plummeted from a healthy 15-22 days to just 10 days or less. This severely impacts clinical practices, complicating treatments across hospitals and home infusion settings. The FDA is actively working to mitigate the crisis, having approved the airlifting of IV sterile products from Baxter's overseas plants, as well as extending shelf lives for over 50 intravenous and irrigation products.

Impact on healthcare

The dire shortage has left healthcare providers scrambling for alternatives, with hospitals facing significant challenges in administering essential IV therapies. The inability to secure adequate supplies not only hinders patient treatment but also places a strain on clinical staff trying to manage emerging needs. Healthcare systems are urged to evaluate infusion protocols, emphasizing the conversion to oral hydration when feasible and optimizing the use of existing IV fluid stocks.

Table: Summary of IV Fluid Shortage Impact

Impact Area Details Consequences
Supply Shortages 60% of national supply lost Increased patient risk
Healthcare Providers >86% report shortages Treatment delays, increased pressure on staff
Stock Duration Reduced from 15-22 days to 10 days or less Compromised patient care
FDA Response Airlifting from overseas plants Temporary relief but ongoing challenges

The compounded effects of the sterile IV fluid shortage highlight the urgent need for adaptive strategies and governance to safeguard patient care amidst healthcare disruptions.

The Essential Role of Sterile Compounding in Infusion Therapy

Sterile Compounding Processes

Sterile compounding is a critical aspect of infusion therapy, as it ensures the preparation of medications in a contaminant-free environment. Compounding personnel are specially trained to maintain the quality and safety of compounded sterile preparations (CSPs). These preparations must be created under strict guidelines, utilizing Primary Engineering Controls (PECs) such as Biological Safety Cabinets and Laminar Airflow Workbenches, which need to meet ISO Class 5 cleanliness standards.

Importance of USP Standards

The United States Pharmacopeia (USP) Chapter 797 provides the essential guidelines that govern sterile compounding practices. This chapter outlines risk levels for CSPs—low, medium, and high—each with specific beyond-use dating (BUD) to ensure medication stability and sterility over time. For instance, low-risk products can have a BUD of 14 days if refrigerated, while high-risk products can only be used for 3 days. Adhering to these standards is vital in minimizing the risk of contamination and infection during administration, particularly in vulnerable patient populations relying on infusion therapies.

Innovations in Sterilization Technologies and Their Impact

New Sterilization Technologies

The landscape of medical device sterilization is evolving as healthcare emphasizes safety and environmental considerations. Ethylene oxide (EtO), traditionally a mainstay in sterilization, is used for approximately 50% of sterile medical devices. Its efficacy is well-documented; however, concerns around safety and environmental impact have spurred interest in alternatives.

The FDA has expanded its guidelines to include new methods. For instance, vaporized hydrogen peroxide (VHP) has been officially recognized as an Established Category A sterilization process. This approach minimizes toxic residuals, making it a favorable option in healthcare settings.

Ethylene Oxide Alternatives

To promote innovation, the FDA has initiated Innovation Challenges, encouraging the development of alternative sterilization methods that do not rely on EtO. These initiatives aim to enhance the safety of sterilization processes while fostering sustainable practices. Companies like ICU Medical and B. Braun Medical are among those exploring and utilizing these advancements to ensure compliance and patient safety.

In summary, as the healthcare industry seeks efficient and environmentally-friendly sterilization solutions, ongoing research and development promise a shift towards safer practices that comply with emerging regulations.

Excellence in Home Infusion: Administrative Methods and Options

Administration Equipment

Home infusion therapy utilizes a variety of administration equipment tailored to patient needs. The most common methods include:

  • Intravenous (IV) Push: A quick method for administering medications directly into the bloodstream, ideal for short treatments but requiring manual effort.
  • Elastomeric Devices: These battery-free pumps like the Easypump enable home administration of medications such as IV antimicrobials, providing users with greater independence.
  • Ambulatory Pumps: Devices such as the CADD-Solis allow continuous or intermittent infusions, facilitating mobility for patients during treatment.

Patient-Centric Choices

When selecting an infusion method, several factors come into play:

  • Medication Stability: Certain drugs necessitate specific administration techniques to maintain effectiveness.
  • Dosing Frequency: The frequency of medication delivery can influence the choice of device, with some options better suited for continuous infusions.
  • Patient Preference: Individual comfort and lifestyle greatly affect equipment choice, ensuring adherence to treatment plans.

Balancing technical requirements with personal convenience promotes optimal patient outcomes in home infusion therapy. Understanding these methods can guide both healthcare providers and patients in making informed decisions.

A Deep Dive into IV Nutrition and Nutritional Support Solutions

Intravenous Nutritional Therapy

Intravenous nutritional therapy, particularly Total Parenteral Nutrition (TPN), plays a pivotal role in the management of patients with feeding difficulties. This therapy provides essential nutrients directly into the bloodstream, bypassing the digestive system, which is crucial for individuals who cannot obtain appropriate nutrition through oral means.

TPN is often used for patients suffering from conditions like Crohn’s disease, cancer, and severe malnutrition, where traditional oral or enteral feeding is ineffective or impossible. It mixes a precise balance of carbohydrates, fats, proteins, vitamins, and minerals tailored to the patient’s requirements.

Benefits of TPN

The benefits of TPN include:

  • Immediate Nutritional Support: Allows for rapid delivery of vital nutrients, promoting healing and recovery.
  • Customizable Formulas: Tailored solutions address specific patient needs, enhancing individual treatment efficacy.
  • Reduced Infections: Delivery in a controlled manner under sterile conditions minimizes the risk of infections that may arise from enteral feeding.

However, the administration of TPN must be carefully monitored by healthcare professionals to detect potential side effects, such as electrolyte imbalances and catheter-related complications.

In summary, intravenous nutritional therapy stands as a critical intervention, bolstered by advancements in medical technology and personalized patient care.

Sterile Injectable Products: Trends and Manufacturing Insights

Trends in Sterile Injectable Products

The sterile injectable market is witnessing significant changes driven by an increased demand for home infusion therapies and the need for safe administration of complex medications. The NHIA's comprehensive Home Infusion Drug List includes over 350 medications, reflecting a notable expansion in sterile injectables tailored for patient care at home. This list, which is compiled from current U.S. dispensing practices, supports home healthcare by providing access to essential medications that would otherwise require hospital stays.

Manufacturing Insights

Manufacturing processes for sterile injectables are evolving in response to increased demand and supply challenges. Major suppliers, such as Baxter and B. Braun Medical, are adapting to ongoing disruptions by relocating inventories and enhancing production capabilities. The FDA's initiatives to extend shelf lives and promote novel sterilization methods highlight the industry's focus on safety and efficiency. Furthermore, advancements in manufacturing standards, including compliance with USP <797>, are pivotal in ensuring the utmost sterility and quality control in compounded sterile preparations.

Category Insights Notable Suppliers
Market Growth Estimated annual growth of 7.5% through 2028 Baxter, B. Braun
Regulatory Standards Compliance with USP <797> for compounding ICU Medical
Technological Advancements Innovations in sterilization procedures
Home Infusion Trend Increased reliance on home settings IU Health Home Infusion

These trends and insights showcase the resilience of the sterile injectable market as it adapts to the changing landscape of patient needs and manufacturing capabilities.

Navigating Supply Interruptions: Strategic Approaches

Coping with Infusion Supply Disruptions

Healthcare providers are currently facing significant challenges caused by supply disruptions, particularly in intravenous (IV) fluids. The recent hurricanes and ongoing shortages have forced providers to seek alternatives, which includes securing sterile solutions from different suppliers or locations. Baxter International, responsible for supplying about 60% of the nation's IV fluids, has been particularly affected, underscoring the importance of diversified sourcing strategies.

A survey by Premier, Inc. highlights that over 86% of healthcare providers are experiencing IV fluid shortages, with many orders remaining partially filled. To mitigate this, the FDA has enabled the airlift of IV sterile products from Baxter's international facilities, providing a short-term solution to the immediate needs.

Resource Management Improvements

In times of supply challenges, innovative resource management becomes crucial. The American Society of Health Systems Pharmacists has recommended strategies such as evaluating the necessity of IV fluids at each shift change and utilizing oral hydration whenever feasible. These measures help optimize existing inventories without compromising patient care.

Moreover, by improving sterilization methods and encouraging novel practices, healthcare providers can ensure that they operate efficiently within the constraints of limited stock. Utilization of advanced sterilization methods, such as vaporized hydrogen peroxide, can enhance the reliability of infection control practices, mitigating the impact of supply shortages on patient safety.

Sterile Infusion Devices: Recent Developments and Innovations

New Equipment Advancements

Recent advancements in sterile infusion devices have greatly improved patient safety and outcomes. Companies like ICU Medical now offer a broad portfolio of intravenous (IV) solutions, including injectables and dedicated parenteral nutrition products. Their flexible containers for intravenous solutions facilitate effective fluid and electrolyte replenishment, enhancing the delivery of essential medications.

Additionally, B. Braun Medical is addressing supply shortages while innovating on their infusion technology, ensuring a reliable stock of IV fluids despite disruptions. The infusion sets tested in the IV UPTRAVI study met rigorous FDA criteria, underscoring the importance of compliance and quality in equipment selection.

Technological Impacts on Infusion Therapy

Technological improvements in sterile medication preparation and delivery have transformed home infusion therapy. Devices such as ambulatory pumps, like the CADD-Solis pump, empower patients with mobility while ensuring reliable medication infusion. Moreover, innovations in compounding sterile preparations (CSPs) are supported by USP standards that ensure safety and sterility in manufacturing, reflecting the ongoing commitment in the industry to minimize contamination risks.

These developments not only support clinical best practices but also make home-based therapies more feasible, addressing the needs of a growing patient population seeking efficient care alternatives.

Future Outlook for Sterile Infusion Solutions: Upcoming Challenges and Innovations

Future of Sterile Infusion

The future of sterile infusion solutions is on the brink of significant advancements. With an increasing patient population in home infusion therapy, estimated to grow at 7.5% annually through 2028, the demand for reliable and safe sterile products is paramount. The NHIA is taking steps to enhance their Home Infusion Drug List, which already catalogues over 350 drugs, ensuring providers can make evidence-based decisions when choosing infusion therapies.

Technological innovations are set to revolutionize how medications are compounded and delivered in sterile environments. The FDA's encouragement for developing novel sterilization methods presents an opportunity for increasing safety standards and minimizing reliance on traditional methods like ethylene oxide sterilization.

Emerging Challenges and Solutions

However, the landscape is not without challenges. Healthcare providers are currently facing difficulties due to shortages in IV fluids and sterile containers, exacerbated by supply chain disruptions, such as those caused by Hurricane Helene. Solutions like relocating inventory and airlifting products from overseas plants are in motion to address these shortages.

Additionally, the implementation of stricter guidelines under USP <797> for the compounding of sterile preparations highlights the ongoing need for healthcare professionals to maintain high standards of patient safety. As challenges arise, the infusion therapy industry’s ability to adapt through innovation and rigorous compliance will play a crucial role in shaping its future.

A Glance Ahead: The Evolving Sphere of Sterile Infusion

The landscape of sterile infusion therapies is continuously evolving, shaped by current global challenges and groundbreaking technological advancements. As healthcare systems adapt to supply shortages and the increasing demand for efficient, sterile treatment options both in clinical settings and at home, the infusion therapy market is poised for substantial growth. Innovations in sterile solutions, compounding methods, and administration technologies will not only enhance treatment efficacy but will also ensure wider accessibility and better patient outcomes. As we look to the future, the commitment to innovation and resilience in supplying sterile infusion products will be critical in shaping healthcare delivery worldwide.

References

Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Show More